A Phase 1 interventional study of PF-06649751 and PF-06649751 in Parkinson's Disease, sponsored by Pfizer. Completed at 17 sites in 2 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-27.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.
Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 1, and was the 1st registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2014.
This study's enrollment of 50 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 57 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Parkinson Disease by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 15 studies in Parkinson Disease by Pfizer, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2014, is one of 5 in phase 1, and was the 10th registered.
Pfizer’s Parkinson Disease studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing tavapadon in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be an open label, dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated daily quaque die (QD) doses given over 21 days (Day 3 to Day 23) to sequential cohorts of subjects with Parkinson's disease. Each cohort will have 2 study periods. For each cohort, subjects will enter Period 1 and if they meet criteria, approximately 12 subjects will be enrolled into Period 2 and dosed with PF 06649751. Based on results observed in a previous study, Cohorts 1 and 2 will not be conducted. Cohorts 3 - 6 will test doses uptitrated to 5 mg, 15 mg and 25 mg QD. Doses may be modified based on emerging safety, tolerability and PK data, but the maximum daily dose that will be given in any cohort will have PK predictions at steady state that are anticipated to be below toxicokinetic limits. An option for down titration to the previous dose level is available should the investigator consider that an AE is intolerable. Following down titration, a single up titration to the next dose level may be attempted if the subject remains symptom free for at least 48 hrs. Safety, tolerability and PK data of Cohort 3 will be reviewed prior to initiating the dosing in Cohorts 4 and 5. Available safety, tolerability and PK data up to Day 24 of at least 5 subjects from Cohorts 4 will be reviewed prior to initiating the dosing in Cohort 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Titration of PF-06649751 up to 5 mg QD
Drug: PF-06649751
Titration of PF-06649751 up to 15 mg QD
Drug: PF-06649751
Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
Drug: PF-06649751
Titration of PF-0649751 up to 25 mg QD
Drug: PF-06649751
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug to the end of study (up to Day 30) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
Time frame: Baseline (Day 1) up to Day 30
Number of Participants With Laboratory Test Abnormalities
Criteria for laboratory abnormalities: Hemoglobin (Hgb),hematocrit, red blood cell(RBC) count: less than(\<)0.8\*lower limit of normal(LLN),mean corpuscular Hgb, mean corpuscular volume, mean corpuscular Hgb concentration:\<0.9\*LLN, greater than (\>)1.1\*upper limit of normal(ULN),platelet:\<0.5\*LLN,\>1.75\*ULN,lymphocyte,neutrophil:\<0.8\*LLN, \>1.2\*ULN, basophil, eosinophil, monocyte:\>1.2\*ULN, WBC:\<0.6\*LLN, \>1.5\*ULN;total bilirubin\>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase:\>3.0\*ULN,total protein,albumin:\<0.8\*LLN,\>1.2\*ULN;blood urea nitrogen,creatinine:\>1.3\*ULN, uric acid\>1.2\*ULN;sodium\<0.95\*LLN,\>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN,\>1.1\*ULN;glucose\<0.6\*LLN,\>1.5\*ULN,urine pH:\<4.5, \>8; urine: WBC, RBC greater than or equal to (\>=)20/high performance field, bacteria: \>20; urobilinogen, urine: glucose, ketone, protein, Hgb, nitrite, leukocyte esterase, bilirubin: \>=1.
Time frame: Baseline up to Day 30
Number of Participants With Vital Sign Abnormalities
Criteria for vital sign abnormality included supine pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine and standing systolic blood pressure (SBP) \<90 millimeter of mercury (mmHg), supine and standing diastolic blood pressure (DBP) \<50 mmHg, supine and standing SBP of \>=30 mmHg maximum (max.) increase from baseline (IFB) and and decrease from baseline (DFB) in same posture, supine and Standing DBP of \>=20 mmHg max. increase and decrease from baseline in same posture. Categories in which there was atleast 1 abnormality are reported in this outcome measure.
Time frame: Baseline up to Day 30
Number of Participants With Electrocardiogram (ECG) Abnormalities
Criteria for ECG abnormalities: maximum PR interval \>=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) \>=25 percent (%) for baseline value of \>200 msec and Pctchg\>=50% for baseline value of \<=200 msec for PR interval, maximum QRS interval \>=140 msec and a maximum IFB: Pctchg\>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to \<480 msec, 480 msec to \<500 msec or \>=500 msec and a maximum change of \<=30change\<60 or \>=60 msec from baseline.
Time frame: Baseline up to Day 30
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
Physical examination included examination of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.
Time frame: Baseline up to Day 30
Number of Participants With Clinically Significant Neurological Examination Abnormality
The complete or full neurological examination included assessment of the cranial nerves; muscle strength, tone, cortical drift, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station. Higher cortical and motor function was considered part of the complete neurological exam. Findings were considered abnormal as confirmed by a certified neurologist.
Time frame: Baseline up to Day 30
Number of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
Time frame: Baseline up to Day 30
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 13
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
Time frame: Baseline, Day 13
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 20
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
Time frame: Baseline, Day 20
Maximum Observed Plasma Concentration (Cmax) of L-Dopa
Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa
Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Apparent Clearance (CL/F) of L-Dopa
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Terminal Half-Life (t1/2) of L-Dopa
Terminal half-life is the time measured for the plasma concentration of drug to decrease by one half. It was calculated as dividing the natural logarithm to the base e (Log e)\*2/k el, where k el is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Area Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa
AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).
Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Area Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa
Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (C last).
Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Apparent Volume of Distribution (Vz/F) of L-Dopa
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Maximum Observed Plasma Concentration (Cmax) of PF-06649751
Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06649751
Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Apparent Clearance (CL/F) of PF-06649751
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 22
Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751
Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Minimum Observed Plasma Trough Concentration (Cmin) of PF-06649751
Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Ratio of Accumulation for Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751
Rac was obtained from AUCtau after last dose divided by AUCtau after first dose, where AUC(tau) = Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
| Milestone | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| Started | 50 | 0 | 0 | 0 | 0 |
| Completed | 45 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Does not meet entrance criteria | 5 | 0 | 0 | 0 | 0 |
| Milestone | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| Started | 0 | 9 | 11 | 6 | 19 |
| Completed | 0 | 9 | 9 | 3 | 8 |
| Not completed | 0 | 0 | 2 | 3 | 11 |
| Withdrew: Adverse event | 0 | 0 | 2 | 2 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 4 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug to the end of study (up to Day 30) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
| participants | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| AEs | 9 | 9 | 7 | 5 | 15 |
| SAEs | 0 | 0 | 0 | 0 | 1 |
Criteria for laboratory abnormalities: Hemoglobin (Hgb),hematocrit, red blood cell(RBC) count: less than(\<)0.8\*lower limit of normal(LLN),mean corpuscular Hgb, mean corpuscular volume, mean corpuscular Hgb concentration:\<0.9\*LLN, greater than (\>)1.1\*upper limit of normal(ULN),platelet:\<0.5\*LLN,\>1.75\*ULN,lymphocyte,neutrophil:\<0.8\*LLN, \>1.2\*ULN, basophil, eosinophil, monocyte:\>1.2\*ULN, WBC:\<0.6\*LLN, \>1.5\*ULN;total bilirubin\>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase:\>3.0\*ULN,total protein,albumin:\<0.8\*LLN,\>1.2\*ULN;blood urea nitrogen,creatinine:\>1.3\*ULN, uric acid\>1.2\*ULN;sodium\<0.95\*LLN,\>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN,\>1.1\*ULN;glucose\<0.6\*LLN,\>1.5\*ULN,urine pH:\<4.5, \>8; urine: WBC, RBC greater than or equal to (\>=)20/high performance field, bacteria: \>20; urobilinogen, urine: glucose, ketone, protein, Hgb, nitrite, leukocyte esterase, bilirubin: \>=1.
| participants | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 17 | 8 | 8 | 5 | 11 |
Criteria for vital sign abnormality included supine pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine and standing systolic blood pressure (SBP) \<90 millimeter of mercury (mmHg), supine and standing diastolic blood pressure (DBP) \<50 mmHg, supine and standing SBP of \>=30 mmHg maximum (max.) increase from baseline (IFB) and and decrease from baseline (DFB) in same posture, supine and Standing DBP of \>=20 mmHg max. increase and decrease from baseline in same posture. Categories in which there was atleast 1 abnormality are reported in this outcome measure.
| participants | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| Supine SBP: <90 mmHg (n =50, 9, 11, 6, 19) | 2 | 1 | 1 | 1 | 1 |
| Standing SBP: <90 mmHg (n =50, 9, 11, 6, 19) | 5 | 2 | 3 | 1 | 0 |
| Supine DBP: <50 mmHg (n =50, 9, 11, 6, 19) | 1 | 1 | 0 | 0 | 1 |
| Max. IFB in Supine SBP: >=30 mmHg (n=50,9,11,6,19) | 1 | 2 | 1 | 0 | 2 |
| Max. IFB in StandingSBP:>=30 mmHg(n= 49,9,11,6,19) | 3 | 1 | 0 | 0 | 2 |
| Max. IFB in Supine DBP: >=20 mmHg(n= 50,9,11,6,19) | 1 | 1 | 2 | 0 | 1 |
| Max. IFB in StandingDBP:>=20 mmHg(n= 49,9,11,6,19) | 1 | 0 | 0 | 0 | 2 |
| Max. DFB in Supine SBP:>=30 mmHg (n= 50,9,11,6,19) | 8 | 1 | 3 | 1 | 5 |
| Max. DFB in StandingSBP:>=30 mmHg(n= 49,9,11,6,19) | 7 | 2 | 4 | 2 | 4 |
| Max. DFB in Supine DBP:>=20 mmHg (n= 50,9,11,6,19) | 9 | 3 | 2 | 3 | 8 |
| Max. DFB in StandingDBP:>=20 mmHg(n= 49,9,11,6,19) | 11 | 2 | 3 | 2 | 5 |
Criteria for ECG abnormalities: maximum PR interval \>=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) \>=25 percent (%) for baseline value of \>200 msec and Pctchg\>=50% for baseline value of \<=200 msec for PR interval, maximum QRS interval \>=140 msec and a maximum IFB: Pctchg\>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to \<480 msec, 480 msec to \<500 msec or \>=500 msec and a maximum change of \<=30change\<60 or \>=60 msec from baseline.
| participants | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Abnormalities | 2 | 0 | 2 | 1 | 2 |
Physical examination included examination of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.
| participants | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings | 0 | 0 | 0 | 0 | 0 |
The complete or full neurological examination included assessment of the cranial nerves; muscle strength, tone, cortical drift, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station. Higher cortical and motor function was considered part of the complete neurological exam. Findings were considered abnormal as confirmed by a certified neurologist.
| participants | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Neurological Examination Abnormality | 0 | 0 | 0 | 0 | 1 |
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
| participants | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Number of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS) | 0 | 0 | 0 | 0 |
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
| hour | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Total OFF time: Baseline (n=9,11,6,19) | 4.42 ± 5.073 | 6.18 ± 3.433 | 6.75 ± 1.789 | 6.05 ± 3.981 |
| Total OFF time: Change at Day 13 (n=9,9,3,9) | -0.14 ± 3.310 | -0.31 ± 4.976 | 1.75 ± 2.646 | -2.44 ± 6.335 |
| Total ON time: Baseline (n=9,11,6,19) | 11.92 ± 5.328 | 9.52 ± 3.665 | 8.13 ± 3.485 | 10.96 ± 4.862 |
| Total ON time: Change at Day 13 (n=9,9,3,9) | 1.86 ± 4.150 | 1.81 ± 6.644 | -4.25 ± 0.750 | 0.06 ± 6.232 |
| ON time WD: Baseline (n=9, 11, 6, 19) | 7.58 ± 5.995 | 8.59 ± 2.996 | 4.13 ± 3.781 | 9.14 ± 5.950 |
| ON time WD: Change at Day 13 (n=9, 9, 3, 9) | -1.50 ± 4.081 | 1.86 ± 6.519 | -1.75 ± 3.031 | -0.78 ± 4.604 |
| ON time with dyskinesia: Baseline (n=9,11,6,19) | 4.33 ± 5.851 | 0.93 ± 1.946 | 4.00 ± 3.698 | 1.82 ± 3.326 |
| ON time with dyskinesia:Change at Day13(n=9,9,3,9) | 3.36 ± 5.460 | -0.06 ± 0.891 | -2.50 ± 2.411 | 0.83 ± 6.294 |
| ON time with TD: Baseline (n=9, 11, 6, 19) | 1.56 ± 2.518 | 0.36 ± 0.876 | 0.29 ± 0.510 | 0.43 ± 1.833 |
| ON time with TD: Change at Day 13 (n=9, 9, 3, 9) | 1.58 ± 2.469 | -0.14 ± 0.417 | 0.25 ± 0.433 | -0.67 ± 2.000 |
| Good ON time: Baseline (n=9, 11, 6, 19) | 10.36 ± 5.053 | 9.16 ± 3.181 | 7.83 ± 3.319 | 10.53 ± 5.165 |
| Good ON time: Change at Day 13 (n=9, 9, 3, 9) | 0.28 ± 2.830 | 1.94 ± 6.690 | -4.50 ± 1.146 | 0.72 ± 5.906 |
| Total Awake time: Baseline (n=9, 11, 6, 19) | 16.33 ± 1.620 | 15.70 ± 1.495 | 14.88 ± 2.602 | 17.01 ± 4.063 |
| Total Awake time: Change at Day 13 (n=9, 9, 3, 9) | 1.72 ± 1.748 | 1.50 ± 3.267 | -2.50 ± 2.883 | -2.39 ± 5.456 |
| Total Asleep time: Baseline (n=9, 11, 6, 19) | 7.67 ± 1.620 | 8.30 ± 1.495 | 7.92 ± 2.053 | 6.24 ± 2.895 |
| Total Asleep time: Change at Day 13 (n=9, 9, 3, 9) | -1.72 ± 1.748 | -1.50 ± 3.267 | -0.33 ± 2.626 | 0.44 ± 0.982 |
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
| hour | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Total OFF time: Change at Day 20 | 1.97 ± 3.166 | -0.19 ± 2.965 | 0.63 ± 4.419 | -1.94 ± 5.603 |
| Total ON time: Change at Day 20 | -1.53 ± 3.556 | 0.69 ± 3.739 | -0.63 ± 3.005 | 0.66 ± 6.518 |
| ON time WD: Change at Day 20 | -2.61 ± 3.814 | 1.06 ± 3.980 | -2.13 ± 3.005 | -0.41 ± 3.659 |
| ON time with dyskinesia: Change at Day 20 | 1.08 ± 5.297 | -0.36 ± 0.730 | 1.50 ± 6.010 | 1.06 ± 8.174 |
| ON time with TD: Change at Day 20 | 0.47 ± 1.910 | -0.08 ± 0.468 | 0.25 ± 0.000 | -0.66 ± 1.856 |
| Good ON time: Change at Day 20 | -2.00 ± 2.613 | 0.78 ± 3.768 | -0.88 ± 3.005 | 1.31 ± 6.088 |
| Total Awake time: Change at Day 20 | 0.44 ± 1.116 | 0.50 ± 2.154 | 0.00 ± 1.414 | -1.28 ± 1.538 |
| Total Asleep time: Change at Day 20 | -0.44 ± 1.116 | -0.50 ± 2.154 | 0.00 ± 1.414 | 1.28 ± 1.538 |
| nanogram per milliliter (ng/mL) | L-Dopa |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of L-Dopa | 2817 ± 60 |
| hour | L-Dopa |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa | 0.517 (0.417 to 8.25) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| liter per hour (L/hr) | L-Dopa |
|---|---|
| Apparent Clearance (CL/F) of L-Dopa | 33.57 ± 37 |
Terminal half-life is the time measured for the plasma concentration of drug to decrease by one half. It was calculated as dividing the natural logarithm to the base e (Log e)\*2/k el, where k el is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| hour | L-Dopa |
|---|---|
| Terminal Half-Life (t1/2) of L-Dopa | 1.534 ± 0.23847 |
AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).
| nanogram*hour per milliliter (ng*hr/mL) | L-Dopa |
|---|---|
| Area Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa | 6117 ± 57 |
Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (C last).
| ng*hr/mL | L-Dopa |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa | 6152 ± 56 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| Liter (L) | L-Dopa |
|---|---|
| Apparent Volume of Distribution (Vz/F) of L-Dopa | 73.41 ± 41 |
| ng/mL | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Day 7 (n =9, 9, 5, 14) | 18.95 ± 51 | 53.69 ± 41 | 31.72 ± 25 | 68.17 ± 23 |
| Day 13 (n =9, 7, 3, 5) | 79.87 ± 27 | 215.7 ± 48 | 143.6 ± 27 | 309.0 ± 20 |
| Day 22 (n =9, 7, 3, 7) | 118.5 ± 33 | 325.4 ± 46 | 241.2 ± 26 | 401.6 ± 41 |
| hour | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Day 7 (n =9, 9, 5, 14) | 1.00 (0.500 to 4.00) | 2.45 (1.03 to 4.15) | 2.00 (1.75 to 4.00) | 3.18 (0.500 to 11.6) |
| Day 13 (n =9, 7, 3, 1) | 2.00 (0.833 to 12.0) | 3.92 (2.03 to 11.8) | 2.00 (2.00 to 4.00) | 8.00 (8.00 to 8.00) |
| Day 22 (n =9, 7, 3, 7) | 2.00 (1.00 to 4.00) | 4.00 (2.00 to 12.0) | 2.02 (2.00 to 4.00) | 4.03 (1.97 to 8.00) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Apparent Clearance (CL/F) of PF-06649751 | 2.377 ± 35 | 2.504 ± 61 | 3.511 ± 40 | 3.483 ± 52 |
Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
| ng*hr/mL | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Day 7 (n =9, 9, 5, 14) | 261.9 ± 30 | 990.8 ± 56 | 530.9 ± 30 | 1203 ± 25 |
| Day 13 (n =9, 7, 3, 5) | 1438 ± 30 | 4192 ± 61 | 2414 ± 39 | 5498 ± 32 |
| Day 22 (n =9, 7, 3, 7) | 2105 ± 35 | 5993 ± 61 | 4271 ± 40 | 7182 ± 52 |
| ng/mL | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|
| Day 7 (n =9, 9, 5, 14) | 7.295 ± 30 | 27.97 ± 66 | 14.19 ± 38 | 24.29 ± 36 |
| Day 13 (n =9, 7, 3, 5) | 35.00 ± 69 | 132.5 ± 77 | 65.19 ± 56 | 162.3 ± 37 |
| Day 22 (n =9, 7, 3, 7) | 68.14 ± 44 | 197.9 ± 78 | 120.8 ± 68 | 215.1 ± 63 |
Rac was obtained from AUCtau after last dose divided by AUCtau after first dose, where AUC(tau) = Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
No measurements were reported for this outcome.
Collected over Baseline (Day 1) up to Day 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| L-Dopa | — | 0/50 (0%) | 8/50 (16%) |
| PF-06649751 5 mg + L-Dopa | — | 0/9 (0%) | 9/9 (100%) |
| PF-06649751 15 mg + L-Dopa | — | 0/11 (0%) | 7/11 (63.6%) |
| PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | — | 0/6 (0%) | 5/6 (83.3%) |
| PF-06649751 25 mg + L-Dopa | — | 1/19 (5.3%) | 15/19 (78.9%) |
| Event | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| PalpitationsCardiac disorders | 0/50 | 0/9 | 0/11 | 0/6 | 1/19 |
| Event | L-Dopa | PF-06649751 5 mg + L-Dopa | PF-06649751 15 mg + L-Dopa | PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID) | PF-06649751 25 mg + L-Dopa |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/50 | 6/9 | 7/11 | 3/6 | 8/19 |
| NauseaGastrointestinal disorders | 4/50 | 0/9 | 3/11 | 2/6 | 8/19 |
| Abdominal discomfortGastrointestinal disorders | 0/50 | 0/9 | 0/11 | 2/6 | 1/19 |
| Neck painMusculoskeletal and connective tissue disorders | 0/50 | 1/9 | 1/11 | 2/6 | 1/19 |
| DizzinessNervous system disorders | 0/50 | 0/9 | 2/11 | 2/6 | 5/19 |
| SomnolenceNervous system disorders | 1/50 | 2/9 | 0/11 | 2/6 | 1/19 |
| Abnormal dreamsPsychiatric disorders | 0/50 | 3/9 | 2/11 | 1/6 | 3/19 |
| AnxietyPsychiatric disorders | 0/50 | 1/9 | 1/11 | 2/6 | 1/19 |
| InsomniaPsychiatric disorders | 3/50 | 3/9 | 0/11 | 0/6 | 0/19 |
| NightmarePsychiatric disorders | 1/50 | 1/9 | 0/11 | 2/6 | 2/19 |
Full analysis set (FAS) included all participants who received at least 1 dose of study medication (L-Dopa or PF-06649751) in Period 1 and/or Period 2.
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 64.2 ± 6.9 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 19 |
| Male | 31 |
The record gives a start of Oct 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tavapadon